Benoxinate
Altafluor Benox (benoxinate) is a small molecule pharmaceutical. Benoxinate was first approved as Benoxinate hydrochloride on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Altafluor benox
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fluorescein sodium and benoxinate hydrochloride | NDA authorized generic | 2023-03-16 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
ATC Codes
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AB: Anesthetics for topical use
— D04AB03: Oxybuprocaine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01H: Local anesthetics, ophthalmologic
— S01HA: Local anesthetics
— S01HA02: Oxybuprocaine
HCPCS
No data
Clinical
Clinical Trials
92 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | 1 | 2 | 9 | 2 | — | 14 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | 1 | — | 2 |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | 1 | — | 1 | |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | 1 | — | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | 1 | — | 1 |
| Coronavirus | D017934 | — | — | — | 1 | — | 1 | ||
| Coronary disease | D003327 | — | — | — | 1 | — | 1 | ||
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | 1 | — | 1 |
| Virus diseases | D014777 | B34 | — | — | — | 1 | — | 1 | |
| Whooping cough | D014917 | EFO_0000650 | A37 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neoplasms | D001749 | C67 | 2 | 10 | 11 | — | — | 22 | |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 8 | 4 | 1 | — | 1 | 13 |
| Urologic neoplasms | D014571 | C64-C68 | 1 | 1 | 3 | — | — | 4 | |
| Healthy volunteers/patients | — | 2 | — | 1 | — | — | 3 | ||
| Colorectal neoplasms | D015179 | 2 | 2 | 1 | — | — | 3 | ||
| Mycobacterium bovis | D009163 | NCBITaxon_1765 | — | — | 2 | — | — | 2 | |
| Neoplasms | D009369 | C80 | — | — | 2 | — | — | 2 | |
| Urologic diseases | D014570 | N39.9 | — | — | 2 | — | — | 2 | |
| Neoplasms by site | D009371 | — | — | 2 | — | — | 2 | ||
| Urinary bladder diseases | D001745 | N32.9 | — | — | 2 | — | — | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | 1 | 1 | — | — | — | 2 | ||
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | — | — | — | 2 |
| Cognitive dysfunction | D060825 | G31.84 | 1 | 1 | — | — | — | 2 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | — | — | — | 1 |
| Hiv | D006678 | O98.7 | — | 1 | — | — | — | 1 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | — | 1 |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | 1 | — | — | — | 1 |
| Nontuberculous mycobacteria | D009170 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | 1 | — | — | — | — | 1 | ||
| Sarcoma | D012509 | 1 | — | — | — | — | 1 | ||
| Neuroblastoma | D009447 | EFO_0000621 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Innate immunity | D007113 | — | — | — | — | 2 | 2 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BENOXINATE |
| INN | oxybuprocaine |
| Description | Oxybuprocaine is a benzoate ester in which 4-amino-3-butoxybenzoic acid and 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester "caine") used especially in ophthalmology and otolaryngology. It has a role as a local anaesthetic, a topical anaesthetic and a drug allergen. It is a benzoate ester, a tertiary amino compound, a substituted aniline and an amino acid ester. It is functionally related to a 2-diethylaminoethanol. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N |
Identifiers
| PDB | — |
| CAS-ID | 99-43-4 |
| RxCUI | 18889 |
| ChEMBL ID | CHEMBL1200 |
| ChEBI ID | 309594 |
| PubChem CID | 4633 |
| DrugBank | DB00892 |
| UNII ID | AXQ0JYM303 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,064 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
648 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more